fb-pixel Skip to main content
The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass.

Biogen cuts Alzheimer’s drug price 50 percent months after approval

The company will reduce the annual list price of the treatment to $28,200 to lower out-of-pocket costs for patients and reduce “the potential financial implications for the US health-care system.”

Newpath Partners raises $350 million for second life science fund

Since launching in 2018, Newpath has partnered with more than 15 scientific founders and participated in large funding rounds for the likes of Neumora Therapeutics and Prime Medicine.

Vertex to advance kidney disease drug after positive early data

It’s an important advance for the Boston biotech, which has been trying to diversify its business beyond cystic fibrosis treatments.

Moderna’s concerns about Omicron outlook spark market slump

Top executives at the Cambridge company reiterated that the Omicron variant’s many mutations suggest new vaccines will be needed, triggering a drop in financial markets.

Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts.
US insurers balk at paying for Biogen’s $56,000-a-year Alzheimer’s treatment
None of the 25 large insurers that responded to a Bloomberg News survey judged the $56,000-a-year drug “medically necessary."

Biogen Inc. headquarters in Cambridge, Massachusetts.
Biogen faces European regulator’s doubts over Alzheimer’s drug
A panel of the European Medicines Agency gave “a negative trend vote” on the U.S. drugmaker’s application, the company said Wednesday.

Latest Headlines in Biotech

Brigham and Women's Hospital in Boston.

Brigham and Women’s Hospital is testing a nasal vaccine for Alzheimer’s disease

The hospital will enroll 16 participants aged 60 to 85 who have an early, symptomatic version of the disease to participate in the early-stage test.

Valo Health, a Boston biotech using artificial intelligence for drug discovery, announced late Monday that it has agreed to end plans to go public via a merger with a special purpose acquisition company.

Valo Health and Khosla Ventures call off $2.8 billion SPAC merger

The companies cited “current market conditions, particularly in the biotechnology area,” as the reason for calling off the deal, announced in June, which would have valued the combined firm at $2.8 billion.

Theonie Anastassiadis, principal at Flagship and Alltrna's cofounder and chief innovation officer (left), and Lovisa Afzelius, an origination partner at Flagship Pioneering and founding chief executive of Alltrna.

Flagship Pioneering unveils another RNA startup, backing it with $50 million

Alltrna aims to use a form of RNA to potentially treat a wide range of diseases.

Nick Leschly, Bluebird’s CEO since 2010, is the new CEO of 2seventy, which was spun off from Bluebird.

Bluebird Bio moving most employees from Kendall Square to Assembly Row

The announcement comes a day after it spun off its cancer drug business to a new publicly traded firm.

Tom Ready of the Fort Point Neighborhood Association, in front of 51 Sleeper St. in Boston, home to one of many office-lab conversions taking place in the Seaport area.

As labs replace offices across Greater Boston, pushback is mounting from wary neighbors

The rapid growth of biotech labs in Greater Boston might end up saving the region’s commercial real estate market, if not its entire economy, from the impacts of the COVID-19 pandemic. But that doesn’t mean everyone wants one to open next door.

Vertex says it's on the right path toward finding a cure for Type 1 diabetes.

Vertex reports positive results for first patient in Type 1 diabetes trial

The Boston-based biotech on Monday unveiled results showing that three months after being injected at Mass. General Hospital with an experimental stem-cell treatment, the patient's daily need for insulin had dropped by more than 90 percent.

Lori Lyons-Williams, Neumora Therapeutics' president and chief operating officer, and Paul Berns, its chief executive officer and chairman.

Neumora hopes to bring precision medicine to brain disease treatments

The Waltham biotech has emerged from stealth mode with $500 million in funding.

As part of the deal, Voyager will receive $30 million upfront and up to $600 million more if the partnership with Pfizer meets certain development, regulatory, and commercial goals.

Voyager Therapeutics signs $30m gene therapy licensing deal with Pfizer

The Cambridge biotech is focused on making the delivery of treatments more efficient.